Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.
User shared 8-month hair loss treatment progress using topical fin/min, topical dut, mk677, RU, and microneedling. They experienced watery semen as a side effect but saw significant improvement in hair growth.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. A user asks about alfatradiol's availability, public perception, and usage in Germany.
User asks about CB-03-01 for hair loss treatment and mentions using topical Dutasteride, TRT, and considering mixing CB-03-01 with Fluridil. CB-03-01 is sold at a high price, and user considers trying a lower concentration.
Hair loss treatments discussed include alfatradiol, big 3, finasteride, RU58841, and stemoxydine. Alfatradiol is less effective but has fewer side effects, and mixing with stemoxydine may improve results.
User experienced hair growth after 1.5 months using Fin, 1 month using Min, and microneedling. They use liquid Rogaine twice daily, microneedle with a .4 mm dermaroller, and take oral Fin once a day.
Oral minoxidil treatment increased hair density and shaft caliber in AGA patients. Side effects included hypertrichosis and lower extremity edema, with younger patients experiencing fewer side effects.
The conversation is about the effectiveness of Dermarolling for hair loss without using Minoxidil. Some people consider using peppermint oil as an alternative.
User "logart89" claims DUT 3 times a week is better than daily FIN for hair loss. Their routine includes DUT, topical DUT, stemoxydine and alfatradiol mix, 5% minoxidil with tretinoin, and weekly derma stamping.
User started DUT 3 times a week, topical minoxidil/tretinoin at night, and topical stemoxydine/alfatradiol mix with tretinoin in the morning for hair loss. They experienced significant progress and no side effects, crediting a YouTuber for encouragement.
Hair loss discussion includes topical spironolactone treatment, used 1-2 times daily for 2 weeks with no changes yet. Minoxidil and Propecia caused nasty side effects for the user.
User tried various hair loss treatments, including natural remedies, topical and oral finasteride, RU with stemoxydine, and topical dutasteride. All treatments had side effects, and topical dutasteride thickened hair but also caused side effects.
User shares 4-month hairline progress using minoxidil, finasteride, nizoral, and dermarolling. Others discuss treatment details and express admiration for the results.
A user has been taking finasteride for 7 months and is experiencing watery semen as the only side effect. They are considering taking zinc supplements to improve this condition.
The user stopped using finasteride after two weeks due to gynecomastia symptoms and shared blood work results questioning if they indicate a cause for the side effects. The user is considering restarting finasteride and seeking advice on their blood work levels in relation to gynecomastia.
Chinese company gets green light for Pyrilutamide Phase II trial for androgenetic alopecia. Androgen receptors downregulate in androgen deficient environments.
Woman uses antiandrogens for hair thinning prevention, experiences severe dry eye with finasteride. Asks if dutasteride could be better despite potential for worse dry eye.
A user asked if anyone who didn't respond to minoxidil saw improvement after adding tretinoin. One person replied they saw hair growth on their hairline after using a combination of minoxidil, finasteride, and tretinoin, suggesting tretinoin may have made them respond to minoxidil.
Topical Dutasteride may halt hair loss and effectively treat androgenic alopecia. Combining low-dose oral Dutasteride with topical application could maximize regrowth and minimize side effects.
The conversation discusses CRISPR-on & CRISPR-off as a potential cure for baldness, contrasting it with hair cloning and other treatments like Minoxidil, finasteride, and RU58841. It also mentions the potential of mRNA for gene expression control and the prioritization of gene editing for severe genetic conditions.
The conversation discusses arranging an interview with the developers of RU58841 to clarify its safety and reasons for halted research, with some users expressing concerns about potential risks and others citing financial reasons for the discontinuation of studies. Specific treatments mentioned include RU58841, minoxidil, and finasteride.
Hair transplants, oral finasteride, oral minoxidil, and dutasteride mesotherapy are highly effective for treating AGA hair loss. This combination can maintain and improve hair for most people, except those with very aggressive AGA.
A user ordered a topical dutasteride gel with tretinoin for hair loss after unsatisfactory results with minoxidil and finasteride. Another user shared their experience with the same product, noting its pleasant smell and feel but difficulty in application and uncertainty about its absorption and frequency of use.
The conversation discusses why CB-03-01, a potential hair loss treatment, isn't widely discussed despite evidence of its effectiveness and safety. Some users mention other treatments like melatonin, procianidin b2, and RU58841, debating their effectiveness and safety.
User shared 6-month progress using finasteride, minoxidil, nizoral, and 2 months of dermarolling for hair loss. Others praised results and asked for details on treatment methods.
The conversation is about a 20-year-old male considering a topical gel combining finasteride, minoxidil, and tretinoin for hair loss, looking to replace his daily minoxidil with this new treatment. He has seen good regrowth with minoxidil but is nervous about starting finasteride.
The emotional impact of hair loss and the risks associated with common treatments such as finasteride, dutasteride, minoxidil, RU58841, and Fluridil. People discussed their personal experiences with these treatments, including potential side effects and lowered fertility. Hair transplants were also mentioned as a possible solution.